Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 6/20 | 0.51 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 0.48 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.48 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.47 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.47 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.46 |
| ▸ | FGFR1 known ✓ | P11362 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 6/20 | 0.59 |
| ▸ | CLK1 | P49759 | 2/20 | 0.59 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.59 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | CLK2 | P49760 | 1/20 | 0.59 |
| ▸ | CLK3 | P49761 | 1/20 | 0.59 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.59 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.59 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 7/20 | 0.52 |
| ▸ | PIM1 | P11309 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141996 | 0.98 | GSK3B (0.61) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1141329 | 0.88 | FGFR1 (0.59) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1141435 | 0.86 | FGFR1 (0.61) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL29732812 | 0.86 | GSK3B (0.65) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL11911439 | 0.86 | GSK3B (0.65) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1141660 | 0.85 | ROCK2 (0.52) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1141318 | 0.83 | ROCK2 (0.53) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL19922226 | 0.83 | CLK1 (0.68) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| Hydrochloric Acid SCHEMBL1142090 | 0.83 | TRPA1 (0.48) | GSK3BCLK1CDK5DYRK1ADYRK3 | |
| SCHEMBL1142257 | 0.81 | TRPA1 (0.49) | GSK3BCLK1CDK5DYRK1ADYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136948-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2025-05-01 | — | — | US | disclosed |
| US-12195762-B2 | Induction of pluripotent cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4206319-A1 | INDUCTION OF PLURIPOTENT CELLS | The Scripps Research Institute (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3235901-B1 | INDUCTION OF PLURIPOTENT CELLS | SCRIPPS RESEARCH INST (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210403878-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2021-12-30 | — | — | US | disclosed |
| CN-113621576-A | Induction of pluripotent cells | 斯克里普斯研究所 | 2021-11-09 | — | — | CN | disclosed |
| CN-105861446-B | Induction of pluripotent cells | 斯克里普斯研究所 | 2021-10-01 | — | — | CN | disclosed |
| US-11046933-B2 | Induction of pluripotent cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-06-29 | — | — | US | disclosed |
| US-20180163181-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2018-06-14 | — | — | US | disclosed |
| US-9909105-B2 | Induction of pluripotent cells | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-03-06 | — | — | US | disclosed |
| CN-1863779-B | indazole derivatives | UBE INDUSTRIES | 2010-05-05 | — | — | CN | disclosed |
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | UBE INDUSTRIES, LTD. (JP) | 2009-10-22 | — | — | US | disclosed |
| US-7563906-B2 | Indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090029970-A1 | PAIN REMEDY CONTAINING ROCK INHIBITOR | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1870099-A1 | PROTECTIVE AGENT FOR RETINAL NEURONAL CELL COMPRISING INDAZOLE DERIVATIVE AS ACTIVE INGREDIENT | Ube Industries, Ltd. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1854484-A1 | PAIN REMEDY CONTAINING ROCK INHIBITOR | Astellas Pharma Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20070129404-A1 | Novel indazole derivatives | UBE INDUSTRIES, LTD. (JP) | 2007-06-07 | — | — | US | disclosed |
| CN-1863779-A | Novel indazole derivative | UBE INDUSTRIES (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1679308-A1 | NOVEL INDAZOLE DERIVATIVE | Ube Industries, Ltd. (JP) | 2006-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264468-A1 | Methods for treating a disease in which Rho kinase is involved | RHOA, ROCK1, RHOT2 | ROCK2 4/4885JAK2 313/4885KDR 2494/4885 |
| US-20070129404-A1 | Novel indazole derivatives | CIT, ROCK1, ROCK2 | ROCK2 3/4885JAK2 629/4885KDR 957/4885 |
| US-20090012123-A1 | Protective Agent for Retinal Neuronal Cell Comprising Indazole Derivative as Active Ingredient | GRIK3, ALDH1A2, GRIN3A | ROCK2 2678/4885JAK2 4880/4885KDR 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.